Public Drug Program Formulary Tables – Psoriasis and Psoriatic Arthritis
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis |
---|---|---|---|---|---|
British Columbia | Biologics and Biosimilars | etanercept | Enbrel® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. |
Alberta | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A. Note: all requests for etanercept for patients weighing 63 kg or more will be assessed for coverage with an etanercept biosimilar. Enbrel will be approved for new etanercept starts for pediatric patients weighing less than 63 kg. | No |
Saskatchewan | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation | Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation |
Manitoba | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. | Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis. |
Ontario | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – L/U | No |
Quebec | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A. If treatment began before August 19, 2020 | Yes – S/A. If treatment began before August 19, 2020 |
New Brunswick | Biologics and Biosimilars | Etanercept | Enbrel® | No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021. |
Nova Scotia | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved. | Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved. |
Prince Edward Island | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. | Yes –S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. |
Nunavut | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes – L/U |
Yukon | Biologics and Biosimilars | Etanercept | Enbrel® | Yes - EDS ; all new etanercept patients will be covered for Brenzys or Erelzi | Yes – EDS; all new etanercept patients will be covered for Erelzi |
NIHB | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes- Only for clients who received approval for Enbrel before October 2, 2017 |
British Columbia | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – EDS | Yes – EDS |
Ontario | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – L/U | Yes – L/U |
Quebec | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Etanercept | Erelzi™ | No | Yes – EDS |
Prince Edward Island | Biologics and Biosimilars | Etanercept | Erelzi™ | No | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes- L/U | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes- L/U | Yes – L/U |
Yukon | Biologics and Biosimilars | Etanercept | Erelzi™ | No | Yes – EDS |
NIHB | Biologics and Biosimilars | Etanercept | Erelzi™ | No | Yes- L/U |
British Columbia | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U | Yes – L/U |
Quebec | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - EDS | Yes - EDS |
Prince Edward Island | Biologics and Biosimilars | Etanercept | Brenzys® | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Brenzys® | No | No |
Nunavut | Biologics and Biosimilars | Etanercept | Brenzys® | No | No |
Northwest Territories | Biologics and Biosimilars | Etanercept | Brenzys® | No | No |
Yukon | Biologics and Biosimilars | Etanercept | Brenzys® | No | Yes – EDS |
NIHB | Biologics and Biosimilars | Etanercept | Brenzys® | No | No |
British Columbia | Biologics and Biosimilars | Adalimumab | Humira® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. |
Alberta | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022. | Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022. |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Humira® | Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab. | Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab. |
Manitoba | Biologics and Biosimilars | Adalimumab | Humira® | Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis. | Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis. |
Ontario | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U | No |
Quebec | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A. If treatment began before August 19, 2020. | Yes - S/A. If treatment began before August 19, 2020. |
New Brunswick | Biologics and Biosimilars | Adalimumab | Humira® | No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021. |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Humira® | Yes- only for clients who received approval for Humira before December 15, 2021 | Yes- only for clients who received approval for Humira before December 15, 2021 |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A | Yes - S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira. | Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira. |
Nunavut | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Humira® | Yes - EDS | Yes - EDS |
NIHB | Biologics and Biosimilars | Adalimumab | Humira® | Yes- only for clients who received approval for Humira before June 11, 2021 | Yes- only for clients who received approval for Humira before June 11, 2021 |
British Columbia | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A |
Alberta | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Hadlima® | No | No |
NIHB | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A |
Alberta | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Hyrimoz® | No | No |
NIHB | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A |
Alberta | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U |
NIHB | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A |
Alberta | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U |
NIHB | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A |
Alberta | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U |
NIHB | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Adalimumab | Abrilada | No | No |
Alberta | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Manitoba | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Ontario | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Quebec | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Abrilada | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
Yukon | Biologics and Biosimilars | Adalimumab | Abrilada | No | No |
NIHB | Biologics and Biosimilars | Adalimumab | Abrilada | Yes – S/A | Yes – S/A |
British Columbia | Biologics and Biosimilars | Adalimumab | Simlandi | No | No |
Alberta | Biologics and Biosimilars | Adalimumab | Simlandi | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Simlandi | Yes – S/A | Yes – S/A |
Manitoba | Biologics and Biosimilars | Adalimumab | Simlandi | Yes – S/A | Yes – S/A |
Ontario | Biologics and Biosimilars | Adalimumab | Simlandi | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Simlandi | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Simlandi | Yes – S/A | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Simlandi | Yes - S/A | Yes - S/A |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Simlandi | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Simlandi | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Simlandi | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Simlandi | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Simlandi | No | No |
NIHB | Biologics and Biosimilars | Adalimumab | Simlandi | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Adalimumab | Yuflyma | No | No |
Alberta | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes – S/A | Yes – S/A |
Manitoba | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes – S/A | Yes – S/A |
Ontario | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes - L/U | Yes - L/U |
Quebec | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Adalimumab | Yuflyma | No | No |
Nova Scotia | Biologics and Biosimilars | Adalimumab | Yuflyma | No | No |
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Yuflyma | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Adalimumab | Yuflyma | No | No |
NIHB | Biologics and Biosimilars | Adalimumab | Yuflyma | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Infliximab | Remicade® | No | No |
Alberta | Biologics and Biosimilars | Infliximab | Remicade® | No | No |
Saskatchewan | Biologics and Biosimilars | Infliximab | Remicade® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Infliximab | Remicade® | Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product. | Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product. |
Ontario | Biologics and Biosimilars | Infliximab | Remicade® | No. May be covered through EAP in specific clinical circumstances . | No. May be covered through EAP in specific clinical circumstances . |
Quebec | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A. If treatment began before August 19, 2020 | Yes – S/A. If treatment began before August 19, 2020 |
New Brunswick | Biologics and Biosimilars | Infliximab | Remicade® | No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021. |
Nova Scotia | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. | Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. |
Prince Edward Island | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). | No |
Nunavut | Biologics and Biosimilars | Infliximab | Remicade® | No | No |
Northwest Territories | Biologics and Biosimilars | Infliximab | Remicade® | No | No |
Yukon | Biologics and Biosimilars | Infliximab | Remicade® | Yes – EDS; all new infliximab patients will be covered for Inflectra brand only. | Yes – EDS; all new infliximab patients will be covered for Inflectra brand only. |
NIHB | Biologics and Biosimilars | Infliximab | Remicade® | No | No |
British Columbia | Biologics and Biosimilars | Infliximab | Avsola® | Yes – S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Infliximab | Avsola® | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Infliximab | Avsola® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Infliximab | Avsola® | Yes - EDS | Yes - EDS |
Ontario | Biologics and Biosimilars | Infliximab | Avsola® | Yes – L/U | Yes – L/U |
Quebec | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - S/A |
New Brunswick | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Infliximab | Avsola® | No | No |
Prince Edward Island | Biologics and Biosimilars | Infliximab | Avsola® | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - SA |
Nunavut | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Infliximab | Avsola® | No | No |
NIHB | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS |
Ontario | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – L/U | Yes – L/U |
Quebec | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A |
New Brunswick | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS |
Prince Edward Island | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – L/U | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – L/U | Yes – L/U |
Yukon | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - EDS | Yes - EDS |
NIHB | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Alberta | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Saskatchewan | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Manitoba | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Ontario | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Quebec | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
New Brunswick | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Nova Scotia | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Prince Edward Island | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Nunavut | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Northwest Territories | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
Yukon | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
NIHB | Biologics and Biosimilars | Infliximab | Omvyence™ | No records available on NIHB website | No records available on NIHB website |
British Columbia | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Alberta | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Saskatchewan | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Manitoba | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Ontario | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Quebec | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
New Brunswick | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Nova Scotia | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Prince Edward Island | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Nunavut | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Northwest Territories | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
Yukon | Biologics and Biosimilars | Infliximab | Remsima™ | No | No |
NIHB | Biologics and Biosimilars | Infliximab | Remsima™ | No records available on NIHB website | No records available on NIHB website |
British Columbia | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS |
Ontario | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – L/U | Yes – L/U |
Quebec | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - S/A | Yes - S/A |
New Brunswick | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - S/A | Yes - S/A |
Nova Scotia | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS |
Prince Edward Island | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U |
Northwest Territories | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U |
Yukon | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U |
NIHB | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U |
British Columbia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes - L/U | Yes - L/U |
Alberta | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS |
Manitoba | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS |
Ontario | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EAP |
Quebec | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS |
Prince Edward Island | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A |
Nunavut | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U |
Yukon | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS |
NIHB | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – L/U |
British Columbia | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – EDS |
Manitoba | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS |
Ontario | Biologics and Biosimilars | Golimumab | Simponi® | N/A | No – EAP may cover in specific clinical circumstances. |
Quebec | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – EDS |
Prince Edward Island | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U |
Yukon | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS |
NIHB | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U |
British Columbia | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS |
Ontario | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | No |
Quebec | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS |
Prince Edward Island | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U |
Yukon | Biologics and Biosimilars | Ixekizumab | Taltz® | No | No |
NIHB | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U |
British Columbia | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A |
Alberta | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A |
Saskatchewan | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | No |
Manitoba | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A |
Ontario | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A |
Quebec | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A |
New Brunswick | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A |
Nova Scotia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A |
Prince Edward Island | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A |
Newfoundland and Labrador | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A |
Nunavut | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | s.o. |
Northwest Territories | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A |
Yukon | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A |
NIHB | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A |
British Columbia | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A |
Alberta | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A |
Saskatchewan | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS |
Ontario | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – L/U | No |
Quebec | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A |
Nova Scotia | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes - EDS |
Prince Edward Island | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A |
Newfoundland and Labrador | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A |
Nunavut | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – L/U | Yes – L/U |
Northwest Territories | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – L/U | Yes – L/U |
Yukon | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS |
NIHB | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – L/U | Yes – L/U |
British Columbia | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No |
Alberta | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No |
Saskatchewan | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | Yes – EDS |
Manitoba | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | No |
Ontario | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No |
Quebec | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | Yes – S/A |
New Brunswick | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No |
Nova Scotia | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes - EDS | No |
Prince Edward Island | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No |
Newfoundland and Labrador | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No |
Nunavut | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No |
Northwest Territories | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No |
Yukon | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | No |
NIHB | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No |
British Columbia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A |
Alberta | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A |
Saskatchewan | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | No |
Manitoba | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A |
Ontario | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A |
Quebec | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A |
New Brunswick | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A |
Nova Scotia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A |
Prince Edward Island | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A |
Newfoundland and Labrador | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A |
Nunavut | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A |
Northwest Territories | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A |
Yukon | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A |
NIHB | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A |
British Columbia | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Alberta | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Saskatchewan | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Manitoba | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Ontario | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Quebec | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
New Brunswick | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Nova Scotia | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Prince Edward Island | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Nunavut | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Northwest Territories | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
Yukon | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
NIHB | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
British Columbia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A |
Alberta | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - SA | N/A |
Saskatchewan | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - EDS | N/A |
Manitoba | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - EDS | N/A |
Ontario | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A |
Quebec | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A |
New Brunswick | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - SA | N/A |
Nova Scotia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – EDS | N/A |
Prince Edward Island | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A |
Newfoundland and Labrador | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – SA | N/A |
Nunavut | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A |
Northwest Territories | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A |
Yukon | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A |
NIHB | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – L/U | N/A |
British Columbia | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Alberta | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Saskatchewan | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Manitoba | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Ontario | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No. EAP may cover in specific clinical circumstances. |
Quebec | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
New Brunswick | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Nova Scotia | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Prince Edward Island | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Nunavut | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Northwest Territories | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
Yukon | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
NIHB | Biologics and Biosimilars | Abatacept | Orencia® | No | No |
British Columbia | Systemic Drugs | Methotrexate | Yes | Yes | |
Alberta | Systemic Drugs | Methotrexate | Yes | Yes | |
Saskatchewan | Systemic Drugs | Methotrexate | Yes | Yes | |
Manitoba | Systemic Drugs | Cyclosporine | Yes | N/A | |
Ontario | Systemic Drugs | Methotrexate | Yes | Yes | |
Quebec | Systemic Drugs | Methotrexate | Yes | Yes | |
New Brunswick | Systemic Drugs | Methotrexate | Yes | Yes | |
Nova Scotia | Systemic Drugs | Methotrexate | Yes | Yes | |
Prince Edward Island | Systemic Drugs | Methotrexate | Yes | Yes | |
Newfoundland and Labrador | Systemic Drugs | Methotrexate | Yes | Yes | |
Nunavut | Systemic Drugs | Methotrexate | Yes | Yes | |
Northwest Territories | Systemic Drugs | Methotrexate | Yes | Yes | |
Yukon | Systemic Drugs | Methotrexate | Yes | Yes | |
NIHB | Systemic Drugs | Methotrexate | Yes | Yes | |
British Columbia | Systemic Drugs | Cyclosporine | Yes – S/A | N/A | |
Alberta | Systemic Drugs | Cyclosporine | Yes – S/A | N/A | |
Saskatchewan | Systemic Drugs | Cyclosporine | Yes – EDS | N/A | |
Manitoba | Systemic Drugs | Cyclosporine | Yes – EDS | N/A | |
Ontario | Systemic Drugs | Cyclosporine | Yes | N/A | |
Quebec | Systemic Drugs | Cyclosporine | Yes | N/A | |
New Brunswick | Systemic Drugs | Cyclosporine | Yes | N/A | |
Nova Scotia | Systemic Drugs | Cyclosporine | Yes | N/A | |
Prince Edward Island | Systemic Drugs | Cyclosporine | Yes | N/A | |
Newfoundland and Labrador | Systemic Drugs | Cyclosporine | Yes | N/A | |
Nunavut | Systemic Drugs | Cyclosporine | Yes | N/A | |
Northwest Territories | Systemic Drugs | Cyclosporine | Yes | N/A | |
Yukon | Systemic Drugs | Cyclosporine | Yes | N/A | |
NIHB | Systemic Drugs | Cyclosporine | Cyclosporine | Yes | N/A |
British Columbia | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Alberta | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Saskatchewan | Systemic Drugs | Acitretin | Soriatane® | Yes – EDS | N/A |
Manitoba | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Ontario | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Quebec | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
New Brunswick | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Nova Scotia | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Prince Edward Island | Systemic Drugs | Acitretin | Soriatane® | Yes-SA | N/A |
Newfoundland and Labrador | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Nunavut | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Northwest Territories | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
Yukon | Systemic Drugs | Acitretin | Soriatane® | Yes – EDS | N/A |
NIHB | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A |
British Columbia | Systemic Drugs | Apremilast | Otezla® | No | No |
Alberta | Systemic Drugs | Apremilast | Otezla® | No | No |
Saskatchewan | Systemic Drugs | Apremilast | Otezla® | No | No |
Manitoba | Systemic Drugs | Apremilast | Otezla® | No | No |
Ontario | Systemic Drugs | Apremilast | Otezla® | No | No |
Quebec | Systemic Drugs | Apremilast | Otezla® | Yes – S/A | No |
New Brunswick | Systemic Drugs | Apremilast | Otezla® | No | No |
Nova Scotia | Systemic Drugs | Apremilast | Otezla® | No | No |
Prince Edward Island | Systemic Drugs | Apremilast | Otezla® | No | No |
Newfoundland and Labrador | Systemic Drugs | Apremilast | Otezla® | No | No |
Nunavut | Systemic Drugs | Apremilast | Otezla® | No | No |
Northwest Territories | Systemic Drugs | Apremilast | Otezla® | No | No |
Yukon | Systemic Drugs | Apremilast | Otezla® | No | No |
NIHB | Systemic Drugs | Apremilast | Otezla® | No | No |
British Columbia | Systemic Drugs | Leflunomide | Arava® | No | No |
Alberta | Systemic Drugs | Leflunomide | Arava® | No | No |
Saskatchewan | Systemic Drugs | Leflunomide | Arava® | No | Yes – EDS |
Manitoba | Systemic Drugs | Leflunomide | Arava® | No | No |
Ontario | Systemic Drugs | Leflunomide | Arava® | Yes | Yes |
Quebec | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
New Brunswick | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
Nova Scotia | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
Prince Edward Island | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
Newfoundland and Labrador | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
Nunavut | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
Northwest Territories | Systemic Drugs | Leflunomide | Arava® | N/A | Yes |
Yukon | Systemic Drugs | Leflunomide | Arava® | No | No |
NIHB | Systemic Drugs | Leflunomide | Arava® | Yes | Yes |
British Columbia | Systemic Drugs | Sulfasalazine | Yes | Yes | |
Alberta | Systemic Drugs | Sulfasalazine | Yes | Yes | |
Saskatchewan | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Manitoba | Systemic Drugs | Sulfasalazine | Yes | Yes | |
Ontario | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Quebec | Systemic Drugs | Sulfasalazine | N/A | Yes | |
New Brunswick | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Nova Scotia | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Prince Edward Island | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Newfoundland and Labrador | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Nunavut | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Northwest Territories | Systemic Drugs | Sulfasalazine | N/A | Yes | |
Yukon | Systemic Drugs | Sulfasalazine | N/A | No | |
NIHB | Systemic Drugs | Sulfasalazine | Yes | Yes | |
British Columbia | Systemic Drugs | Celecoxib | No | Yes – S/A | |
Alberta | Systemic Drugs | Celecoxib | No | No | |
Saskatchewan | Systemic Drugs | Celecoxib | Yes | Yes | |
Manitoba | Systemic Drugs | Celecoxib | Yes | Yes | |
Ontario | Systemic Drugs | Celecoxib | N/A | No | |
Quebec | Systemic Drugs | Celecoxib | N/A | Yes | |
New Brunswick | Systemic Drugs | Celecoxib | N/A | Yes | |
Nova Scotia | Systemic Drugs | Celecoxib | N/A | No | |
Prince Edward Island | Systemic Drugs | Celecoxib | N/A | Yes | |
Newfoundland and Labrador | Systemic Drugs | Celecoxib | N/A | Yes | |
Nunavut | Systemic Drugs | Celecoxib | N/A | Yes | |
Northwest Territories | Systemic Drugs | Celecoxib | N/A | Yes | |
Yukon | Systemic Drugs | Celecoxib | N/A | Yes | |
NIHB | Systemic Drugs | Celecoxib | Yes | Yes | |
British Columbia | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Alberta | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Saskatchewan | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Manitoba | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Ontario | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Quebec | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
New Brunswick | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Nova Scotia | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Prince Edward Island | Systemic Drugs | Tofacitinib | Xeljanz® | No | No |
Newfoundland and Labrador | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
Nunavut | Systemic Drugs | Tofacitinib | Xeljanz® | No | No |
Northwest Territories | Systemic Drugs | Tofacitinib | Xeljanz® | No | No |
Yukon | Systemic Drugs | Tofacitinib | Xeljanz® | No | No |
NIHB | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No |
British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes – L/U | N/A |
Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes - EDS | N/A |
Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes – L/U | N/A |
Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – EDS | N/A |
Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – in specific clinical situations | N/A |
Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – S/A | N/A |
New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – EDS | N/A |
Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – S/A | N/A |
Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A |
British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A |
Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A |
Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes – in specific clinical situations | N/A |
Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes – S/A | N/A |
New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A |
Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A |
Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A |
British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | No | N/A |
Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes – in specific clinical situations | N/A |
Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes – S/A | N/A |
New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes – EDS | N/A |
Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A |
British Columbia | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
Alberta | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
Saskatchewan | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
Manitoba | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
Ontario | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
Quebec | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
New Brunswick | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes – S/A | N/A |
Nova Scotia | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes – EDS | N/A |
Prince Edward Island | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes – S/A | N/A |
Nunavut | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
Northwest Territories | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
Yukon | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
NIHB | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
British Columbia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Alberta | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes - SA | N/A |
Saskatchewan | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Manitoba | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
Ontario | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Quebec | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
New Brunswick | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
Nova Scotia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Prince Edward Island | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Newfoundland and Labrador | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Nunavut | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Northwest Territories | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
Yukon | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
NIHB | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
British Columbia | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Alberta | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Saskatchewan | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Manitoba | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Ontario | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Quebec | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
New Brunswick | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Nova Scotia | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Prince Edward Island | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Newfoundland and Labrador | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Nunavut | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Northwest Territories | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
Yukon | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
NIHB | Biologics and Biosimilars | Bimekizumab | Bimzelx® | No | No |
British Columbia | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Alberta | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | Yes – S/A |
Saskatchewan | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | Yes – EDS |
Manitoba | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Ontario | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Quebec | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | Yes – S/A |
New Brunswick | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Nova Scotia | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Prince Edward Island | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Newfoundland and Labrador | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Nunavut | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Northwest Territories | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
Yukon | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | No |
NIHB | Systemic Drugs | Upadacitinib | Rinvoq® | N/A | Yes- L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.